DATA AND REPRODUCIBILITY

Journal of Ophthalmology (Ukraine) supports and encourages research data to be shared, discoverable, citable, and recognized as an intellectual product of value. Authors are increasingly encouraged to use of reporting guidelines and registration of clinical trials and other study designs according to standard practice in ophthalmology.

Reporting Guidelines

Reporting guidelines have been developed for different study designs:

CONSORT (https://www.consort-spirit.org/ ) for randomized trials

STROBE for observational studies (https://www.strobe-statement.org/ )

PRISMA for systematic reviews and meta-analyses (https://www.prisma-statement.org/ )

ARRIVE: animals in research: reporting in vivo experiments (https://arriveguidelines.org/ )

STARD for studies of diagnostic accuracy (https://www.equator-network.org/reporting-guidelines/stard/ ).

EQUATOR Network (https://www.equator-network.org/ )

NLM's Research Reporting Guidelines and Initiatives www.nlm.nih.gov/services/research_report_guide.html ).

Authors are encouraged to follow these guidelines because they help authors describe the study in enough detail for it to be evaluated by editors, reviewers, readers, and other researchers evaluating the medical literature.

 

Registration of clinical trials

Registration in a public trials registry is a condition for publication of clinical trials in Journal of Ophthalmology (Ukraine) in accordance with International Committee of Medical Journal Editors recommendations. Journal of Ophthalmology (Ukraine) requires registration of clinical trials in a public trials registry at or before the time of first patient enrollment as a condition of consideration for publication.

The ICMJE defines a clinical trial as any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the relationship between a health-related intervention and a health outcome.  Health-related interventions are those used to modify a biomedical or health-related outcome; examples include drugs, surgical procedures, devices, behavioral treatments, educational programs, dietary interventions, quality improvement interventions, and process-of-care changes. Health outcomes are any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. The ICMJE does not define the timing of first participant enrollment, but best practice dictates registration by the time of first participant consent.

Journal of Ophthalmology (Ukraine) accepts publicly accessible registration in any registry that is a primary register of the WHO International Clinical Trials Registry Platform (ICTRP) (https://www.who.int/clinical-trials-registry-platform ). Approval to conduct a study from an independent local, regional or national review body (e.g., ethics committee, institutional review board) does not fulfill the ICMJE requirement for prospective clinical trial registration.

Journal of Ophthalmology (Ukraine) publishes the trial registration number at the end of the abstract. Whenever a registration number is available, authors list this number the first time they use a trial acronym to refer either to the trial they are reporting or to other trials that they mention in the manuscript.

 

Data Sharing and Data Accessibility

Journal of Ophthalmology (Ukraine) encourages authors to share the data supporting the results in the paper by archiving it in an appropriate public repository.

Research data refers to the results of observations or experimentation that validate research findings, which may also include software, code, models, algorithms, protocols, methods and other useful materials related to the paper.

We encourage authors to provide a data availability statement, including a link to the repository they have used, in order that this statement can be published in their paper.

 

Data Availability Statement

Data availability statements should include information on where data supporting the results reported in the article can be found including, where applicable, hyperlinks to publicly archived datasets analyzed or generated during the study. By data we mean the minimal dataset that would be necessary to interpret, replicate and build upon the findings reported in the article. If it is not possible to share your data, use the statement to confirm why it cannot be shared.

Examples:

The datasets generated during and/or analyzed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS].

The datasets generated during and/or analyzed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

The data that support the findings of this study are available from [third party name] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [third party name].

Data citation

Shared data should be cited. When data is available and linked, authors will need to provide a citation of the data in their reference list.